What one share of Arrowhead Pharmaceuticals holds
The Company develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes.
Arrowhead Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $4.79 |
|---|---|
| Profit | −$2.29 |
| Capex (buildings and equipment) | $0.11 |
| Free cash flow | −$0.54 |
| Cash and investments | $0.39 |
| Book value | $3.30 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2010 | — | −$0.90 | — | — | — | $1.26 |
| 2011 | — | −$0.40 | $0.00 | −$0.98 | — | $1.48 |
| 2012 | — | −$1.90 | $0.04 | −$1.42 | — | $0.74 |
| 2013 | — | −$1.30 | $0.01 | −$0.81 | — | $0.85 |
| 2014 | — | −$1.25 | $0.04 | −$0.79 | — | $3.05 |
| 2015 | — | −$1.60 | $0.03 | −$1.18 | — | $1.85 |
| 2016 | — | −$1.34 | $0.06 | −$1.12 | — | $1.37 |
| 2017 | — | −$0.47 | $0.11 | −$0.43 | — | $1.09 |
| 2018 | — | −$0.65 | $0.02 | −$0.58 | — | $1.08 |
| 2019 | — | $0.69 | $0.12 | $1.63 | — | $2.56 |
| 2020 | — | −$0.84 | $0.12 | −$1.07 | — | $4.51 |
| 2021 | — | −$1.36 | $0.23 | $1.42 | — | $3.92 |
| 2022 | — | −$1.67 | $0.50 | −$1.79 | — | $3.76 |
| 2023 | — | −$1.92 | $1.66 | −$3.10 | — | $2.53 |
| 2024 | — | −$5.00 | $1.18 | −$5.05 | — | $1.49 |
| 2025 | $6.20 | −$0.01 | $0.17 | $1.17 | — | $3.43 |
Common questions about Arrowhead Pharmaceuticals
How much does one share of Arrowhead Pharmaceuticals earn?
Over the last 12 months, Arrowhead Pharmaceuticals lost $2.29 for each share on $4.79 of sales.
Does Arrowhead Pharmaceuticals pay a dividend?
Arrowhead Pharmaceuticals didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Arrowhead Pharmaceuticals’s book value per share?
Arrowhead Pharmaceuticals’s book value is $3.30 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Arrowhead Pharmaceuticals have?
Each share of Arrowhead Pharmaceuticals has $0.39 of cash and investments, as of June 30, 2026.
What is Arrowhead Pharmaceuticals’s free cash flow per share?
−$0.54 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Arrowhead Pharmaceuticals bought back shares?
Arrowhead Pharmaceuticals’s share count rose about 1979% from 2010 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.